Remove 2015 Remove Biosimilars Remove Chemotherapy
article thumbnail

Good news for Lilly as sintilimab hits the spot in lung cancer again

pharmaphorum

Innovent has only released top-line data from the 480-subject ORIENT-31 study so far, but said sintilimab given with its bevacizumab biosimilar Byvasda on top of chemotherapy with Lilly’s own Alimta (pemetrexed) and cisplatin had a statistically significant improvement in PFS.

article thumbnail

Unpleasant truth: the pandemic, record debt and our opportunity for sustainability

pharmaphorum

billion in 2015. In my role at Sandoz, I work with teams that are passionately trying to drive healthcare sustainability through the increased use of high-quality biosimilars. Beyond significant cost savings, biosimilar uptake has been shown to simultaneously improve patient access, varying by country. In fact, an estimated 21.2

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Top 20 Drugs with US Patent Expiry in 2023 Based on Total Sales Value

PharmaShots

Some companies accept the offered period and open doors to biological drugs or biosimilars. It is the only drug in its class of chemotherapy and is developed from the natural substance found in a sea sponge. As of now, there are no the US FDA approved biosimilars available for Actemra.

article thumbnail

Beating the Big C

Pharmaceutical Technology

Analysts predict Pfizer’s revenue stream would be slashed by 25% by 2015 if the company did not branch out into other areas. “Companies used to be universally protected by patents but there is a pathway to approval opening up for biosimilar legislation. .